Trade-Ideas: LifePoint Health (LPNT) Is Today's Weak On High Relative Volume Stock
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified LifePoint Health as such a stock due to the following factors:
- LPNT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $26.7 million.
- LPNT has traded 166,782 shares today.
- LPNT is trading at 3.13 times the normal volume for the stock at this time of day.
- LPNT is trading at a new low 6.01% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in LPNT with the Ticky from Trade-Ideas. See the FREE profile for LPNT NOW at Trade-Ideas
More details on LPNT:
LifePoint Health, Inc., through its subsidiaries, operates general acute care hospitals primarily in non-urban communities in the United States. LPNT has a PE ratio of 22. Currently there are 6 analysts that rate LifePoint Health a buy, 2 analysts rate it a sell, and 11 rate it a hold.
The average volume for LifePoint Health has been 459,900 shares per day over the past 30 days. LifePoint Health has a market cap of $3.2 billion and is part of the health care sector and health services industry. The stock has a beta of 0.78 and a short float of 4.1% with 4.72 days to cover. Shares are up 3.1% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates LifePoint Health as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins.
Highlights from the ratings report include:
- LPNT's revenue growth has slightly outpaced the industry average of 10.2%. Since the same quarter one year prior, revenues rose by 12.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 58.5% when compared to the same quarter one year prior, rising from $27.50 million to $43.60 million.
- Net operating cash flow has increased to $174.30 million or 32.74% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 11.26%.
- LIFEPOINT HEALTH INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past year indicate the company has sound management over its earnings and share float. We anticipate these figures will begin to experience more growth in the coming year. During the past fiscal year, LIFEPOINT HEALTH INC's EPS of $2.69 remained unchanged from the prior years' EPS of $2.69. This year, the market expects an improvement in earnings ($4.04 versus $2.69).
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that the other strengths this company displays justify these higher price levels.
- You can view the full LifePoint Health Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.